Evidence map›Paper›PMID 38270218›Full record

ArticleCarcinogenesis2024

Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer.

Chameera Ekanayake Weeramange, Kai Dun Tang, Darryl Irwin, Gunter Hartel, Julian Langton-Lockton, Rahul Ladwa, Lizbeth Kenny, Touraj Taheri, Bernard Whitfield, Sarju Vasani and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Carcinogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Chameera Ekanayake WeeramangeSaliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery (GRIDD), Griffith University, Nathan, Queensland 4111, Australia.
Kai Dun TangEDA School of Biological Sciences and Biotechnology, Nankai International Advanced Research Institute (Shenzhen Futian), Nankai University, Tianjin, 300071, P.R. China.
Darryl IrwinAgena Bioscience, Bowen Hills, Queensland 4006, Australia.
Gunter HartelStatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Queensland 4006, Australia.
Julian Langton-LocktonMetro-North Sexual Health and HIV Service, Brisbane, Queensland 4000, Australia.
Rahul LadwaDepartment of Cancer Care Services, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia.
Lizbeth KennyFaculty of Medicine, The University of Queensland, Herston, Queensland 4006, Australia.
Touraj TaheriFaculty of Medicine, The University of Queensland, Herston, Queensland 4006, Australia.
Bernard WhitfieldDepartment of Otolaryngology, Head and Neck Surgery, Princess Alexandra and Logan Hospitals, Meadowbrook, Queensland 4131, Australia.
Sarju VasaniFaculty of Medicine, The University of Queensland, Herston, Queensland 4006, Australia.
Chamindie PunyadeeraSaliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery (GRIDD), Griffith University, Nathan, Queensland 4111, Australia.
Griffith University · AURoyal Brisbane and Women's Hospital · AUMetro South Health · AUNankai University · CNPrincess Alexandra Hospital · AUQIMR Berghofer Medical Research Institute · AUThe University of Queensland · AU

Funding

National Health and Medical Research Council APP 2012560University Grants Commission
6 · The paper itself

Abstract

Despite the rising incidence, currently, there are no early detection methods for HPV-driven HNC (HPV-HNC). Cervical cancer studies suggest that HPV DNA methylation changes can be used as a biomarker to discriminate cancer patients from HPV-infected individuals. As such, this study was designed to establish a protocol to evaluate DNA methylation changes in HPV late genes and long control region (LCR) in saliva samples of HPV-HNC patients and HPV-positive controls. Higher methylation levels were detected in HPV late genes (L1 and L2) in both tumour and saliva samples of HPV-HNC patients compared with HPV-positive controls. Moreover, methylation patterns between tumours and corresponding saliva samples were observed to have a strong correlation (Passing-Bablok regression analysis; τ = 0.7483, P < 0.0001). Considering the differences between HNC and controls in methylation levels in late genes, and considering primer amplification efficiencies, 13 CpG sites located at L1 and L2 genes were selected for further evaluation. A total of 18 HNC saliva samples and 10 control saliva samples were assessed for the methylation levels in the selected sites. From the CpG sites evaluated statistically significant differences were identified for CpG sites at L2-CpG 6 (P = 0.0004), L1-CpG 3 (P = 0.0144), L1-CpG 2 (P = 0.0395) and L2-CpG 19 (P = 0.0455). Our pilot data indicate that higher levels of DNA methylation in HPV late genes are indicative of HPV-HNC risk, and it is a potential supplementary biomarker for salivary HPV detection-based HPV-HNC screening.

Indexed as

Head and Neck NeoplasmsPapillomavirus InfectionsBiomarkersDNA MethylationDNA, ViralFemaleHuman Papillomavirus VirusesHumansPapillomaviridaeBiomarkersDNA, Viral

Identifiers

PMID38270218
PMCPMC10925951
OpenAlexW4391211862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.